CompoAtlas

APO-K 600mg

Originaltext auf Französisch.

In Kanada zugelassenes natürliches Gesundheitsprodukt

Falls dieses Produkt in Frankreich verkauft würde

Nach den von uns angewandten Vorschriften wurde kein Punkt festgestellt.

Eine Tagesmenge wird nur bei ausdrücklicher oraler Dosierung für Erwachsene berechnet, die pro Tag und in einer zur Produktform passenden festen Einheit angegeben ist. Mehrdeutige Einheiten, Flüssigkeiten, Pulver und pädiatrische Dosen werden nicht hochgerechnet. Eine nicht berechnete Menge wird nicht mit Dosisgrenzwerten verglichen. Diese Analyse stellt weder eine Verkaufszulassung in Frankreich noch eine Sicherheits- oder Wirksamkeitsbewertung dar.

Zusammensetzung

Arzneilicher Inhaltsstoff und QuelleJe Dosiseinheit laut QuelleTäglich höchstens, Erwachsene
Chlorure de potassium600 mgNicht berechnet

Nicht arzneiliche Inhaltsstoffe

Dioxyde de titane, Sunset Yellow FCF Aluminium Lake, Quinoline Yellow WS, Silicon dioxide colloïdal, Stéarate de magnésium, Hypromellose, Poly(éthylène glycol), Hydroxypropylcellulose, Ethylcellulose

In Kanada empfohlene Dosen

BevölkerungsgruppeAlterMenge pro EinnahmeHäufigkeit
AdultesNon préciséeminimum : 5 Comprimé ; maximum : 12 Comprimé1 Tous les jours
AdultesNon précisée3 Comprimé1 Tous les jours

In Kanada zugelassene Verwendungen

Potassium Supplement.

Originaltext auf Französisch.

Eine in Kanada zugelassene Verwendung ist keine in der Europäischen Union zugelassene gesundheitsbezogene Angabe. Beachten Sie das Register gesundheitsbezogener Angaben.

Warnhinweise in Kanada

Précautions et mises en garde : In patients with impaired mechanisms for excreting potassium, administration of potassium salts can produce hyperkalemia and cardiac arrest. This occurs commonly in patients given potassium by the i.v. route but may also occur in patients given potassium orally. Potentially fatal hyperkalemia can develop rapidly and by asymptomatic. The use of potassium salts in patients with chronic renal disease, or any other condition which impairs potassium excretion, requires particularly careful monitoring of the serum potassium concentration and appropriate dosage adjustment. ACE inhibitors (e.g. captopril, enalapril) will produce some potassium retention by inhibiting aldoterone production. In patients receiving ACE inhibitors, therefore potassium supplements should only be given under close monitoring. Hypokalemia in patients with metabolic acidosis should be treated with an alkalinizing potassium salt such as potassium acetate, potassium bicarbonate or potassium citrate. A probable assocation exists between the use of coated tablets containing potassium salts, with or without thiazide diuretics, and the incidence of serious small bowel ulceration. Such preparations should be used only when adequate dietary supplementation is not practical, and should be discontinued if abdominal pain, distention, nausea, vomiting or gastrointestinal bleeding occurs. Apo-K is a wax matrix tablet formulated to provide a controlled rate of release of potassium chloride and thus to minimize the possibility of a high local concentration of potassium near the bowel wall. While the reported frequency of small bowel lesions is very much less with wax matrix tablets (less than 1/100,000 patient years) than with enteric coated potassium chloride tablets (40 to 50/100,000 patient years), a few cases associated with wax matrix tablets have been reported. Apo-K should be discontinued immediately and the possibility of bowel obstruction or perforation considered if pronounced nausea, severe vomiting, diarrhea, abdominal pain, distention gastrointestinal bleeding occurs. Such risks may be increased in patients with esophageal stasis, known peptic and/or gastric ulcers, delayed intestinal transit, or intestinal ischemia due to generalized atherosclerotic vascular disease. Precautions - Periodic serum potassium deteminations are recommended during long-term potassium supplementation. When blood samples are taken for the analysis of plasma potassium, it is important to remember that artificial elevations can occur after an improper venipuncture technique or as a result in vitro hemolysis of the sample.

Originaltext auf Französisch.

Précautions et mises en garde : The correction of hypokalemia, particularly in the presence of cardiac disease, renal disease or acidosis requires careful attention to acid-base balance and appropriate monitoring of serum electrolytes, the electrocardiogram and the clinical status of the patient. Potassium supplements should be used with caution in diseases associated with heart block since increased serum potassium may increase the degree of block. Patients with ostomies may have an altered intestinal transit time and are better treated with other forms of potassium salt. In some patients, diuretic-induced magnesium deficiency will prevent the restoration of intracellular deficits of potassium, so that hypomagnesemia should be corrected at the same time as hypokalemia. Pregnancy - In general, no drug should be taken during the first trimester, and the benefits and risks or drug administration should be carefully considered throughout pregnancy. Lactation - The normal K+ content of human milk is approximately 13 mEq/L. Since oral potassium becomes part of the body's potassium pool, provided the body potassium is not excessive, the contribution of Apo-K can be expected to have little or no effect on the potassium level in human milk. Drug Interactions - Concomitant treatment with potassium sparing diuretics is contraindicated. Apo-K should be used with caution in patient's receiving agents known to have a potential for hyperkalemia, such as ACE inhibitors (e.g. captopril, enalpril; see Warnings), NSAIDS (e.g. indomethacin), beta-blockers, Heparin and digoxin. Since anticholinergic agents have the potential to reduce gastrointestinal motility, they should be prescribed with caution when given concomitantly with sold oral potassium preparations, particularly in high doses. Children - Safety and effectiveness in children have not been established. Geriatrics - As renal function, and hence the potential for maintaining potassium balance may decrease with age, serum potassium levels should be monitored regularly and dosage adjusted as appropriate. As gastrointestinal motility may also be affected by age, elderly patients should be reminded to swallow solid oral potassium salts with adequate amounts of fluid.

Originaltext auf Französisch.

Contre-indications : Hypersensitivity to potassium administration, e.g. in adynamia episodica hereditaria or congenital paramyotonia. Hyperkalemia of any entiology, since a further increase in the serum potassium concentration in such patients can produce cardiac arrhythmia and cardiac arrest. Hyperkalemia may complicate any of the following conditions: marked renal failure, untreated Addison's disease, hyperadrenalism associated with adrenogenital syndrome, hypoeninemic hypoaldosteronism, extensive tissue breakdown (as in severe burns, trauma, massive hemolysis, rhabdomyolysis, tumour lysis), acute dehydration, heat cramps, metabolic acidosis. Renal impairment with oliguria or azotemia. Concomitant administration of Apo-K and potassium sparing diuretics (e.g. spironolactone, triamterene or amiloride). Patients in whom there is cause for arrest or delay in tablet passage through the gastrointestinal tract. These states include: partial or complete esophageal displacement due to cardiac surgery (e.g. valve replacement); stenosis or atony in any part of the gastrointestinal tract (e.g. pyloric stenosis, intestinal structures). In these instances, potassium supplementation should be with a liquid preparation.

Originaltext auf Französisch.

Effets indésirables connus : The most common adverse reactions to oral potassium salts are nausea, vomiting, flatulence, abdominal discomfort and diarrhea. These symptoms are due to irritation of the gastrointestinal tract and are best avoided by increasing fluid intake when possible, taking the dose with meals or reducing the dose. One of the most severe adverse effects is hyperkalemia (see Warnings). There have also been reports of esophageal and gastrointestinal obstruction, bleeding, ulceration or perforation (see Warnings). Small bowel lesions have been reported following the administration of Apo-K, the incidence is much lower than that reported for enteric-coated potassium chloride tablets (see Warnings). Pruritus and/or skin rash, as well as urticaria, have been reported rarely.

Originaltext auf Französisch.

Produktdaten

Inhaber
Apotex Inc.
NPN oder DIN-HM
00602884
Status
Aktive Lizenz
Lizenzdatum
30. Juli 2008
Überarbeitungsdatum
Nicht angegeben
Form
Comprimé
Verabreichungsweg
Orale
Art des Antrags
DIN de transition

Quelle

Amtlicher Health-Canada-Eintrag, Zulassung 00602884

Licensed Natural Health Products Database (LNHPD), Health Canada: zugelassene Produkte, Inhaltsstoffe, Dosierungen, Verwendungen und Warnhinweise, abgerufen am 27. Oktober 2026.

Contains information licensed under the Open Government Licence – Canada (Health Canada, LNHPD)

Originaltext auf Englisch.

Licence du gouvernement ouvert – Canada 2.0 (OGL-Canada 2.0)

Originaltext auf Französisch.

Die unter demselben Namen in Europa verkaufte Rezeptur kann abweichen. Diese Angaben ersetzen keinen ärztlichen oder pharmazeutischen Rat.

Das Belegdatum dieser Zutatenliste ist unbekannt.

Das Produkt hat sich geändert? Fotografieren Sie die Verpackung.

Ist eine Angabe zu diesem Produkt falsch oder veraltet, ob Sie Leser oder Marke sind? Schreiben Sie an contact@compoatlas.com: Jede Korrektur wird im Korrekturprotokoll veröffentlicht.

Eingabetaste zum Analysieren, Umschalt+Eingabetaste für eine neue Zeile